We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+9.46%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$11.9B
AUM Growth
+$1.4B
(+13%)
Cap. Flow
+$748M
Cap. Flow
% of AUM
6.3%
Top 10 Holdings %
Top 10 Hldgs %
12.11%
Holding
747
New
202
Increased
220
Reduced
153
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$134M |
| 2 |
STMicroelectronics
STM
|
+$103M |
| 3 |
Meta Platforms (Facebook)
META
|
+$89.9M |
| 4 |
MetLife
MET
|
+$71.9M |
| 5 |
Gilead Sciences
GILD
|
+$70.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TE Connectivity
TEL
|
+$161M |
| 2 |
Eli Lilly
LLY
|
+$153M |
| 3 |
MRSH
Marsh
MRSH
|
+$123M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$91.8M |
| 5 |
Electronic Arts
EA
|
+$79.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.43% |
| 2 | Technology | 17.4% |
| 3 | Industrials | 8.07% |
| 4 | Energy | 6.4% |
| 5 | Financials | 6.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Union Pacific
UNP
$176B
| $11.3M | 0.09% |
45,691
+7,985
| +21% | +$1.94M |
|
|
DAWN
277
DELISTED
Day One Biopharmaceuticals
DAWN
| $11.1M | 0.09% |
797,333
+89,802
| +13% | +$1.28M |
|
278
Rocket Pharmaceuticals
RCKT
$382M
| $11.1M | 0.09% |
601,063
+39,097
| +7% | +$801K |
|
|
FOLD
279
DELISTED
Amicus Therapeutics
FOLD
| $11M | 0.09% |
+1,028,287
| New | +$11.2M |
|
280
Baidu
BIDU
$37.7B
| $10.8M | 0.09% |
+102,622
| New | +$9.06M |
|
281
Fate Therapeutics
FATE
$303M
| $10.7M | 0.09% |
3,065,747
+2,063,745
| +206% | +$8.03M |
|
282
Addus HomeCare
ADUS
$2.17B
| $10.7M | 0.09% |
80,636
+55,836
| +225% | +$7.05M |
|
283
Spectrum Brands
SPB
$2.09B
| $10.6M | 0.09% |
+111,897
| New | +$9.9M |
|
284
DoorDash
DASH
$90.3B
| $10.6M | 0.09% |
+74,266
| New | +$9.01M |
|
285
Astrana Health
ASTH
$1.77B
| $10.6M | 0.09% |
182,564
+91,006
| +99% | +$4.47M |
|
286
Ternium
TX
$10.5B
| $10.5M | 0.09% |
+285,758
| New | +$9.98M |
|
287
Americold
COLD
$4B
| $10.4M | 0.09% |
+369,642
| New | +$10.6M |
|
288
Viatris
VTRS
$20.6B
| $10.4M | 0.09% |
893,414
+3,914
| +0.4% | +$45.2K |
|
289
Sysco
SYY
$40.3B
| $10.3M | 0.09% |
132,283
-70,002
| -35% | -$5.26M |
|
290
Globus Medical
GMED
$11.1B
| $10.3M | 0.09% |
143,699
+5,171
| +4% | +$365K |
|
|
HOLX
291
DELISTED
Hologic
HOLX
| $10.3M | 0.09% |
+126,000
| New | +$10.1M |
|
|
VRE
292
DELISTED
Veris Residential
VRE
| $10.2M | 0.09% |
+568,975
| New | +$9.38M |
|
293
argenx
ARGX
$54.3B
| $10.1M | 0.08% |
18,581
-38,190
| -67% | -$19.3M |
|
294
Middleby
MIDD
$6.12B
| $9.95M | 0.08% |
71,511
+56,197
| +367% | +$7.55M |
|
295
Intellia Therapeutics
NTLA
$1.53B
| $9.9M | 0.08% |
+481,752
| New | +$11.1M |
|
296
AerCap
AER
$24.4B
| $9.86M | 0.08% |
104,113
+76,180
| +273% | +$7.14M |
|
297
Paylocity
PCTY
$8.18B
| $9.81M | 0.08% |
59,488
+54,779
| +1,163% | +$8.33M |
|
298
Savara
SVRA
$1.13B
| $9.77M | 0.08% |
+2,305,195
| New | +$10.2M |
|
|
ORKA
299
Oruka Therapeutics
ORKA
$5.86B
| $9.58M | 0.08% |
+390,795
| New | +$13.6M |
|
300
Packaging Corp of America
PKG
$22.8B
| $9.55M | 0.08% |
+44,342
| New | +$8.81M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q3 2024 Portfolio in Review
As of Q3 2024, Woodline Partners held 747 positions worth $11.9B, up 13% from $10.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Woodline Partners deployed $748M of net new capital in Q3 2024, opening 202 new positions and adding to 220 existing holdings. Its largest new stake was ASML: 149,876 shares worth $125M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 42% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Eli Lilly, an estimated $153M trimmed.
- Woodline Partners's largest Q3 2024 buy was ASML: 149,876 shares worth $125M.
- Woodline Partners added most to STMicroelectronics in Q3 2024, an estimated $103M increase.
- Woodline Partners's biggest Q3 2024 reduction was Eli Lilly, cutting an estimated $153M.
- Woodline Partners fully exited TE Connectivity in Q3 2024, selling an estimated $161M.
- Woodline Partners's ten largest holdings make up 12% of its $11.9B portfolio in Q3 2024.
- Woodline Partners opened 202 new positions and closed 161 in Q3 2024.
- Woodline Partners's portfolio value rose 13% quarter-over-quarter to $11.9B.
Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.